Navigation Links
Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
Date:6/22/2011

JERUSALEM, Israel, June 22, 2011 /PRNewswire/ --


 

Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB), a biotech company with a novel platform technology for the oral delivery of drugs currently only available via injection, announced today that Dr. Michael Berelowitz, M.D., has been appointed the Chairman of its Scientific Advisory Board (SAB).

Dr. Berelowitz joined Oramed's Board of Directors in May 2010 and will now expand his role as Chairman of the SAB.  Moving forward, he will be actively involved in the Company's scientific decisions, clinical strategy, and partnership negotiations.  

Dr. Berelowitz has extensive experience as an academic endocrinologist as well as expertise in clinical research and drug development.  Most recently, he served as the Senior Vice President and Head of Clinical Development and Medical Affairs in the Specialty Care Business Unit at Pfizer.  Dr. Berelowitz joined Pfizer in 1996, after several years in academia, as a Medical Director on the Diabetes Disease Management Team. Among his public activities, Dr. Berelowitz has served on the board of directors of the American Diabetes Association and the Clinical Initiatives Committee of the Endocrine Society.  He has also chaired the Task Force on Research of the New York State Council on Diabetes and has served on several editorial boards. Dr. Berelowitz has authored and co-authored more than 100 peer-reviewed journal articles and book chapters in the areas of pituitary growth hormone regulation, diabetes and metabolic disorders.

"Dr. Berelowitz is a renowned industry leader with a special interest in and knowledge of diabetes. His expertise in this expanded role will be invaluable as Oramed continues to advance its clinical trials and business development efforts," said Nadav Kidron, Chief Executive Officer of Oramed.

Dr. Berelowitz commented, "I am honored and excited about m
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
2. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
3. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
4. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
5. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
6. Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
7. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
8. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
9. Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
10. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
11. Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 /PRNewswire-iReach/ -- Tute Genomics, the leader ... an agreement with Lineagen, Inc., to provide ... Dx PLUS.  Lineagen, focused on the ... currently offers FirstStep Dx PLUS, a ... by healthcare providers as a first-line genetic ...
(Date:7/10/2014)... 2014 -- According to the International Atomic Energy ... comes from terrorists acquiring sufficient quantities of plutonium ... crude nuclear explosive device. The IAEA also notes ... involved gram-level quantities, which can be challenging to ... a new study appearing this week in the ...
(Date:7/10/2014)... the journal PNAS (Proceedings of the National Academy ... and sleep deprivation have a significant effect on our ... the best time of day to test for diseases ... medicines effectively. , Researchers from the University of Surrey ... links between sleep deprivation, body clock disruption and metabolism, ...
(Date:7/10/2014)... The lithium-ion batteries that power our laptops and electric ... a single charge with the help of a sponge-like ... to replace the graphite traditionally used in one of ... times the energy storage capacity of graphite. A paper ... was published today in Nature Communications . , ...
Breaking Biology Technology:Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Sensitive detection method may help impede illicit nuclear trafficking 2Time of day crucial to accurately test for diseases, new research finds 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3
... SuperGen Inc.,(Nasdaq: SUPG ), a pharmaceutical company ... therapies for solid tumors and,hematological malignancies, today announced ... Officer is scheduled to present at the Thomas,Weisel ... the Four,Seasons Hotel in Boston. SuperGen,s presentation ...
... Aug. 29 Caliper Life,Sciences, Inc. (Nasdaq: ... the,Thomas Weisel Partners Healthcare Conference 2007 will be ... Kevin Hrusovsky, President and CEO,of Caliper, will be ... http://www.veracast.com/webcasts/twp/healthcare07/98209449.cfm . An archived,presentation will be available for ...
... Aug. 28 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS, Nasdaq: PXSL) ... of,Bronchitol for the treatment of people with bronchiectasis ... life and mucus clearance. Data from the ... quality of life after 12 weeks of treatment ...
Cached Biology Technology:Phase III Trial Finds Pharmaxis' Bronchitol Effective 2Phase III Trial Finds Pharmaxis' Bronchitol Effective 3
(Date:7/11/2014)... addition to the hippocampus, the marginal division of ... memory. What is the impact degree of substance ... and memory function? Yan Yu and his team, ... found, using immunofluorescence staining, that substance P receptor, ... and striatal marginal division of normal rats. Unilateral ...
(Date:7/11/2014)... -- Research and Markets has announced the ... Industry Analysis Size Share Growth Trends and Forecast to ... http://photos.prnewswire.com/prnh/20130307/600769 The rising number ... for high level security in both private and public ... username and passwords, tokens etc. are vulnerable to attacks. ...
(Date:7/10/2014)... Albuquerque, and other major cities in New Mexico, nearly ... municipal wastewater rather than precious potable water supplies. Across ... of all golf courses receive treated effluent. Reusing the ... Additionally, golf courses and homeowners alike fertilize their lawns ... is nitrate. A New Mexico State University turfgrass expert ...
Breaking Biology News(10 mins):International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2'Tailored' water -- the latest in lawn care 2
... is available in French . Montreal -- ... consumers, thanks to Concordia University researchers who,ve developed a new ... products. "Even though Canada does not allow the use ... there were no methods or equipment to effectively measure residual ...
... With concerns about jobs in the headlines around the world, ... ( C&EN ) presents a 3-part cover story on the ... than 96% of all manufactured goods, with the chemical industry ... C&EN is the weekly newsmagazine of the American Chemical ...
... and BGI, the world,s largest genomics institute, today ... conduct large-scale human genome sequencing and bioinformatics analysis ... at Children,s Hospital. The partnership will focus on ... pediatric diseases using next-generation sequencing. The Center became ...
Cached Biology News:Children's Hospital of Philadelphia and BGI announce partnership and new Joint Genome Center 2
Yersinia pestis...
... WinList come straight from the folks who ... automatic region positioning, N-Stat regions, and presentation-quality ... thoughtful conversations, and careful design. Of course, ... are still there, too. WinList leads the ...
Insect Cell Lysis Buffer 50 ml...
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Biology Products: